(E)-3-(m-fluorophenyl)-2-propenyl bromide | 1234462-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-(m-fluorophenyl)-2-propenyl bromide
• 英文别名: 1-[(E)-3-bromoprop-1-enyl]-3-fluorobenzene
• CAS: 1234462-92-0
• 化学式: C₉H₈BrF
• 分子量: 215.065
• InChiKey: UKJCWYQRTHHKOM-DUXPYHPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-3-(m-fluorophenyl)-2-propenyl bromide 在 (+)-苯并四咪唑 、 二异丙胺 作用下， 以 四氢呋喃 、 氘代二甲亚砜 、 氘代乙腈 、 水 、 乙腈 为溶剂， 反应 5.25h， 生成 (±)-4-nitrophenyl (anti)-2-(dimethylamino)-3-(4-fluorophenyl)pent-4-enoate
  参考文献：
  名称：

  烯丙基铵叶立德的催化对映选择性 [2,3]-重排：机理和计算研究

  摘要：

  描述了异硫脲催化的烯丙基铵叶立德的对映选择性 [2,3] 重排的机理研究。使用 19F NMR 和密度泛函理论计算的反应动力学分析阐明了反应曲线并允许识别催化剂静止状态和周转率限制步骤。已经观察到催化相关的催化剂 - 底物加合物，其组成通过 13C 和 15N 同位素标记明确阐明。同位素夹带表明观察到的催化剂-底物加合物是催化生产循环中真正的中间体。已经检查了 HOBt 作为添加剂对反应、催化剂静止状态和周转率限制步骤的影响。交叉实验已经探讨了催化循环中每个建议步骤的可逆性。计算也被用来阐明立体控制的起源，1,5-S···O 相互作用和催化剂立体定向基团提供了过渡结构刚性和对映选择性，同时偏爱阳离子-π 相互作用而不是 C-H···π负责非对映选择性。

  DOI：

  10.1021/jacs.6b11851
• 作为产物：
  描述：

  (E)-3-(3-fluorophenyl)prop-2-en-1-ol 在 三溴化磷 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 (E)-3-(m-fluorophenyl)-2-propenyl bromide
  参考文献：
  名称：

  [2+2] 氧化可见光光催化环加成

  摘要：

  光化学反应因其能够轻松组装环丁烷和其他使用其他常规合成方法难以构建的应变环系统而著称。我们之前已经表明 Ru(bpy)(3)(2+) 是一种有效的光催化剂，可以促进缺电子烯烃在可见光下的 [2+2] 环加成反应。在这里，我们表明 Ru(bpy)(3)(2+) 也是富电子烯烃 [2+2] 环加成的有效光催化剂。这种转变是由 Ru(bpy)(3)(2+) 的多功能光电化学特性实现的，它可以在适当的条件下对感兴趣的有机底物进行单电子还原或单电子氧化。

  DOI：

  10.1021/ja103934y

文献信息

• [2+2] Cycloadditions by Oxidative Visible Light Photocatalysis
  作者：Michael A. Ischay、Zhan Lu、Tehshik P. Yoon

  DOI：10.1021/ja103934y

  日期：2010.6.30

  cyclobutanes and other strained ring systems that are difficult to construct using other conventional synthetic methods. We have previously shown that Ru(bpy)(3)(2+) is an efficient photocatalyst that promotes the [2+2] cycloadditions of electron-deficient olefins with visible light. Here, we show that Ru(bpy)(3)(2+) is also an effective photocatalyst for the [2+2] cycloaddition of electron-rich olefins

  光化学反应因其能够轻松组装环丁烷和其他使用其他常规合成方法难以构建的应变环系统而著称。我们之前已经表明 Ru(bpy)(3)(2+) 是一种有效的光催化剂，可以促进缺电子烯烃在可见光下的 [2+2] 环加成反应。在这里，我们表明 Ru(bpy)(3)(2+) 也是富电子烯烃 [2+2] 环加成的有效光催化剂。这种转变是由 Ru(bpy)(3)(2+) 的多功能光电化学特性实现的，它可以在适当的条件下对感兴趣的有机底物进行单电子还原或单电子氧化。
• Inter- and Intramolecular Cyclopropanations of Diazo Weinreb Amides Catalyzed by Ruthenium(II)-<i>Amm</i> -Pheox
  作者：Hamada S. A. Mandour、Soda Chanthamath、Kazutaka Shibatomi、Seiji Iwasa

  DOI：10.1002/adsc.201601345

  日期：2017.5.17

  diazo Weinreb amides and trans-allylic diazo Weinreb amide derivatives have been achieved using chiral ruthenium(II)-Amm-Pheox catalyst to give the corresponding chiral cyclopropyl Weinreb amides in excellent yield (up to 99%) with excellent enantioselectivity (up to 99% ee). The chiral products could easily undergo useful synthetic transformations to give the corresponding aldehydes, alcohols and

  使用手性钌（II）-Amm- Pheox催化剂已经实现了一系列重氮Weinreb酰胺和反式烯丙基重氮Weinreb酰胺衍生物的分子间和分子内环丙烷化，从而以优异的收率（高达99％）获得了相应的手性环丙基Weinreb酰胺）具有出色的对映选择性（高达99％ee）。手性产物可以容易地进行有用的合成转化，以高产率和对映选择性得到相应的醛，醇和酮。
• Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate <i>Staphylococcus aureus</i> Infections in Vivo
  作者：Shuaishuai Ni、Hanwen Wei、Baoli Li、Feifei Chen、Yifu Liu、Wenhua Chen、Yixiang Xu、Xiaoxia Qiu、Xiaokang Li、Yanli Lu、Wenwen Liu、Linhao Hu、Dazheng Lin、Manjiong Wang、Xinyu Zheng、Fei Mao、Jin Zhu、Lefu Lan、Jian Li

  DOI：10.1021/acs.jmedchem.7b00949

  日期：2017.10.12

  Our previous work (Wang et al. J. Med. Chem. 2016, 59, 4831-4848) revealed that effective benzocycloalkane-derived staphyloxanthin inhibitors against methicillin-resistant Staphylococcus aureus (S. aureus) infections were accompanied by poor water solubility and high hERG inhibition and dosages (preadministration). In this study, 92 chroman and coumaran derivatives as novel inhibitors have been addressed for overcoming deficiencies above. Derivatives 69 and 105 displayed excellent pigment inhibitory activities and low hERG inhibition, along with improvement of solubility by salt type selection. The broad and significantly potent antibacterial spectra of 69 and 105 were displayed first with normal administration in the livers and hearts in mice against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate S. aureus), and NRS271 (linezolid-resistant S. aureus), compared with linezolid and vancomycin. In summary, both 69 and 105 have the potential to be developed as good antibacterial candidates targeting virulence factors.
• Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant <i>Staphylococcus aureus</i>
  作者：Shuaishuai Ni、Baoli Li、Feifei Chen、Hanwen Wei、Fei Mao、Yifu Liu、Yixiang Xu、Xiaoxi Qiu、Xiaokang Li、Wenwen Liu、Linghao Hu、Dazheng Ling、Manjiong Wang、Xinyu Zheng、Jin Zhu、Lefu Lan、Jian Li

  DOI：10.1021/acsmedchemlett.7b00501

  日期：2018.3.8

  Diapophytoene desaturase (CrtN) is a potential novel target for intervening in the biosynthesis of the virulence factor staphyloxanthin. In this study, 38 1,4-benzodioxan-derived CrtN inhibitors were designed and synthesized to overwhelm the defects of leading compound 4a. Derivative 47 displayed superior pigment inhibitory activity, better hERG inhibitory properties and water solubility, and significantly sensitized MRSA strains to immune clearance in vitro. Notably, 47 displayed excellent efficacy against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate MRSA, VISA), and NRS271 (linezolid-resistant MRSA, LRSA) comparable to that of linezolid and vancomycin in vivo.
• Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity
  作者：Baoli Li、Shuaishuai Ni、Fei Mao、Feifei Chen、Yifu Liu、Hanwen Wei、Wenhua Chen、Jin Zhu、Lefu Lan、Jian Li

  DOI：10.1021/acs.jmedchem.7b01300

  日期：2018.1.11

  CrtN has been identified as an attractive and druggable target for treating pigmented Staphylococcus aureus infections. More than 100 new compounds were synthesized, which target the overwhelming the defects of the CrtN inhibitor 1. Analogues 23a and 23b demonstrated a significant activity against pigmented S. aureus Newman and 13 MRSA strains (IC50 = 0.02-10.5 nM), along with lower hERG inhibition (IC50 > 30 mu M, similar to 10-fold decrease in comparison with 1). Furthermore, 23a and 23b were confirmed to reduce the staphylococcal load in the kidney and heart in a mouse model with normal treatment deeper than pretreatment ones, comparable even with vancomycin and linezolid. Remarkably, 23a could strongly block the pigment biosynthesis of these nine multidrug-resistant MRSA strains, including excellent activity against LRSA strains and VISA strains in vivo, and all of which demonstrated that 23a has a huge potential against intractable MRSA, VISA, and LRSA issues as a therapeutic drug.